ROS1 and non-small cell lung carcinoma: Crizotinib is approved for the treatment of ROS1-positive, advanced NSCLC (investigator-assessed ORR 72% (95% CI: 58–84))35; lorlatinib, taletrectinib and repotrectinib are next-generation ROS1 inhibitors that are currently under investigation for the treatment of patients with ROS1-positive NSCLC who are treatment-naive and who have received previous treatment, including ROS1 TKIs36–38.